Digital biomarker startup Koneksa scores $45M in Collection C funding

Digital biomarker startup Koneksa introduced a $45 million Collection C funding spherical to gasoline the enlargement of its scientific group and its scientific platform. AyurMaya led the spherical, with participation from Takeda Ventures, Velocity Capital, McKesson Ventures, Merck International Well being Innovation Fund, Novartis (dRx Capital) Spring Mountain Capital and Waterline Ventures. 

This brings the New York-based firm’s complete funding to roughly $65 million. 

WHAT IT DOES

Centered on serving to researchers speed up drug discovery, the corporate developed an algorithm-based platform that is ready to analyze and combine uncooked knowledge from wearable and sensors. 

The startup created quite a few biometric monitoring instruments that may be built-in into analysis. Purchasers can select to include an at-home spirometry, actigraphy, gait and balance-monitoring device, and a vital-sign monitoring device into their analysis. The system additionally features a real-time affected person alert and notification system. 

“Digital biomarkers are revolutionizing translational science and scientific apply, each bit as impactful as pharmacogenetics or circulating cell-free tumor DNA biomarkers. COVID-19, the rise of distant monitoring, and digital scientific trials created the circumstances for fast adoption and success of digital biomarkers. Elevated use of digital biomarkers by biopharmaceutical corporations will result in extra lifesaving therapies for sufferers,” Dr. John A. Wagner, chief medical officer at Koneksa, mentioned in a press release. 

WHAT IT’S FOR 

The corporate plans to make use of the brand new money to develop its digital-biomarker platform and the self-service instruments in its clinical-data-integration merchandise. It additionally plans to construct out its science group, together with including Wagner as its first chief medical officer. 

MARKET SNAPSHOT 

Over the previous couple of years, life science corporations and researchers have demonstrated curiosity within the digital biomarker area. In 2016, Takeda announced a collaboration with Koneska Health targeted on utilizing the startup’s biosensor instruments within the former’s scientific trials.

Koneska is not the one firm working within the digital biomarker area. Sonde makes use of vocal biomarkers to assist consider for sure situations. Its instruments embrace a vocal-screening device for respiratory illness symptoms, in addition to a vocal biomarker to assist evaluate mental wellness

Apple and Biogen teamed up on researchers utilizing digital biomarkers to assist detect early-stage cognitive decline. The tech big can be working with UCLA researchers to take a look at how wearables and telephone knowledge might detect melancholy.

Source

Leave a Reply